Filing Flows › 8-K events › Karyopharm Therapeutics
Karyopharm Therapeutics: regulation fd disclosure
Form 8-K filed Nov 2, 2026 · items 7.01
FDA decisionsKaryopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
What the filing says
Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future – The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis –
Read the filing on SEC EDGAR →
Karyopharm Therapeutics at a glance
Latest quarterQ2 2026
Revenue$33.4M
Revenue Y/Y-12%
Operating margin-67.4%
IndustryPharmaceutical Preparations
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%. The chart follows the revenue to costs, profit and cash.
Karyopharm Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →
Karyopharm Therapeutics’s other material 8-Ks
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.